Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone in pediatric bipolar mania (REACH)
NCT00076115Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Dec 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of risperidone in bipolar I disorder (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Change in Total Young Mania Rating Scale Score at 3 weeks. Started Dec 2003; status: completed.
02
Drugs
risperidone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT00076115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076115.